STOCK TITAN

LeMaitre Vascular (LMAT) Stock News, Dec 2020-May 2021

LMAT NASDAQ

LeMaitre Vascular, Inc. provides devices, implants, and services for the treatment of peripheral vascular disease. The company develops, manufactures, and markets disposable and implantable vascular devices for vascular surgeons, with products used in arteries and veins.

Recurring LMAT news includes quarterly financial results, guidance, dividend declarations, and management presentations at healthcare investor conferences. Company updates also discuss product categories such as Artegraft, grafts, valvulotomes, and carotid shunts, along with sales activity across the Americas, EMEA, and Asia Pacific.

News
Rhea-AI Summary

LeMaitre (Nasdaq:LMAT) announced the receipt of CE marks for five vascular products after a prior lapse due to a change in notified bodies. The newly certified products include XenoSure Biologic Patches, AlboGraft Polyester Vascular Grafts, and various Carotid Shunts, with expiration dates extending to 2024. Notably, the XenoSure's indications no longer cover neuro or cardiac applications. Andrew Hodgkinson highlighted that despite some product line losses totaling 3% of EMEA sales, customer supplies remained largely uninterrupted due to existing inventory.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.08%
Tags
none
-
Rhea-AI Summary

LeMaitre Vascular, Inc. (Nasdaq:LMAT) will have its CFO, JJ Pellegrino, present at the Jefferies Virtual Healthcare Conference on June 4, 2021, at 1:30 PM EDT. The company specializes in devices and services for peripheral vascular disease, which affects over 200 million individuals globally. LeMaitre develops and markets both disposable and implantable vascular devices aimed at vascular surgeons. For more details, visit www.lemaitre.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.06%
Tags
conferences
-
News
Rhea-AI Summary

LeMaitre (Nasdaq:LMAT) reported Q1 2021 results showing sales of $35.9 million, a 17% increase year-over-year, despite a 5% organic decline. Net income reached $5.9 million, up 87%, with earnings per share of $0.28, also an 83% increase. Sales in the Americas and Asia/Pac grew significantly, while Europe/Middle East/Africa experienced a decline. The company declared a quarterly dividend of $0.11 per share, to be paid on June 3, 2021. For Q2 2021, LeMaitre projects sales between $37 million and $40 million, with a gross margin of 66.7%. Their share repurchase program has been authorized for up to $15 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.58%
Tags
Rhea-AI Summary

LeMaitre Vascular announced its participation in two upcoming investor conferences in May 2021. David Roberts, President, will present at the 7th Annual Truist Securities Life Sciences Summit on May 4, 2021. He will also be featured at the UBS Global Healthcare Virtual Conference on May 26, 2021, at 9:00 AM EDT. LeMaitre specializes in devices and services for treating peripheral vascular disease, impacting over 200 million people globally. The firm develops vascular devices tailored for vascular surgeons. More information is available at lemaitre.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.81%
Tags
conferences
-
Rhea-AI Summary

LeMaitre Vascular, Inc. (Nasdaq: LMAT) will release its Q1 2021 financial results on April 29, 2021, after market close. A conference call is scheduled for 5:00 PM EDT on the same day to discuss the financial results, business highlights, and outlook. Interested parties can access the call via phone or a live webcast. LeMaitre is known for its vascular devices, addressing the needs of vascular surgeons and catering to a global patient base affected by peripheral vascular disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags
-
Rhea-AI Summary

LeMaitre Vascular announced that CFO JJ Pellegrino will present at the 20th Annual Needham Virtual Healthcare Conference on April 12, 2021, at 9:30 AM EDT. The company specializes in devices and services for treating peripheral vascular disease, which affects over 200 million people globally. LeMaitre develops and markets both disposable and implantable vascular devices tailored for vascular surgeons. For further information, visit www.lemaitre.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.43%
Tags
conferences
News
Rhea-AI Summary

LeMaitre (Nasdaq: LMAT) reported strong Q4 2020 results, with sales of $37.5 million, a 24% increase year-over-year. Operating income surged 94% to $9.5 million, resulting in a net income of $7.0 million and earnings of $0.34 per diluted share. Debt was reduced by $21.5 million, improving the balance sheet. Despite gross margin slightly declining to 65%, the company achieved record sales driven by acquisitions and strong performance in the Americas. For Q1 2021, LeMaitre projects sales between $33.8 and $36.8 million, with an expected earnings per share of $0.24 to $0.31.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.64%
Tags
-
Rhea-AI Summary

LeMaitre Vascular (Nasdaq:LMAT) is set to participate in four key investor conferences in February and March 2021. David Roberts, President, will present at:

  • SVB Leerink's Global Healthcare Conference on February 26, 2021, at 8:40 AM EST
  • Barclays Global Healthcare Conference on March 9, 2021, at 1:50 PM EST
  • 33rd Annual Roth Conference on March 15, 2021, on demand
  • Oppenheimer's Healthcare Conference on March 16, 2021, at 3:10 PM EDT

LeMaitre Vascular specializes in devices and services for peripheral vascular disease, helping over 200 million people globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.51%
Tags
conferences
-
Rhea-AI Summary

LeMaitre Vascular, Inc. (Nasdaq:LMAT) will release its fourth quarter 2020 financial results on February 25, 2021, post-market. A conference call is scheduled for the same day at 5:00 PM ET to discuss results and company outlook. Investors can dial in or access the call via a webcast at www.lemaitre.com/investor. LeMaitre is known for its devices addressing peripheral vascular disease, a condition impacting over 200 million individuals globally, and offers a diversified product portfolio for vascular surgeons.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.39%
Tags
Rhea-AI Summary

LeMaitre Vascular (Nasdaq:LMAT) announced its participation in two upcoming investor conferences in January 2021. CFO JJ Pellegrino will present at the 23rd Annual Needham Virtual Growth Conference on January 11, 2021, at 11:30 AM ET, and at the Sidoti Winter 2021 Investor Conference on January 14, 2021, at 10:45 AM ET. The company, which specializes in devices for treating peripheral vascular disease, aims to inform and engage investors about its market position and growth strategies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.80%
Tags
conferences

FAQ

What is the current stock price of LeMaitre Vascular (LMAT)?

LeMaitre Vascular (LMAT) last closed at $74.86.

What is the market cap of LeMaitre Vascular (LMAT)?

The market cap of LeMaitre Vascular (LMAT) is approximately $1.7B.